Searchable abstracts of presentations at key conferences in endocrinology

ea0081oc11.2 | Oral Communications 11: Thyroid 2 | ECE2022

What you choose makes the difference: the first medical therapy for amiodarone-induced thyrotoxicosis has significant implications on cardiovascular events and hospitalizations

Cappellani Daniele , Cosentino Giada , Morganti Riccardo , Manetti Luca , Bartalena Luigi , Bogazzi Fausto

Context: Amiodarone is a widely used anti-arrhythmic medication, however associated with a 15-20% rate of thyroid adverse effects. Amiodarone-induced thyrotoxicosis (AIT) is a complex disease due to diagnostic difficulties and therapeutic challenges. AIT patients often receive initial therapy for thyrotoxicosis before admission to a referral center. Whether the first-line medical therapy (i.e. therapies for thyrotoxicosis at first diagnosis of AIT) may affect the outcome of AI...

ea0081ep774 | Pituitary and Neuroendocrinology | ECE2022

Cushing’s syndrome due to adrenocorticotropic hormone-secreting metastatic neuroendocrine pancreatic tumor: diagnostic workup and management

Cosentino Giada , Manetti Luca , Marconcini Giulia , Boggi Ugo , Marconcini Riccardo , Lupi Isabella , Cappellani Daniele , Urbani Claudio , Bogazzi Fausto

We report the clinical history of a 21-years old young female who, in February 2021, presented abdominal pain and biliary vomiting that lasted for two months. An esophagus-gastroduodenoscopy revealed a duodenal ulcerative lesion and proton pump inhibitory therapy was started with clinical benefit. One month later, the patient presented a facial acneiform rush with hirsutism for which she was referred to our attention. An abdominal MRI documented a well-circumscribed hyper-vasc...

ea0070aep332 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Immune checkpoint inhibitors (ICIs) and ‘Fulminant Diabetes’: Two emblematic cases

Sgro’ Daniele , Giannarelli Rosa , Aragona Michele , Viola Nicola , Cosentino Giada , Brancatella Alessandro , Latrofa Francesco , Del Prato Stefano , Santini Ferruccio , Marcocci Claudio , Lupi Isabella

Context: Programmed cell death protein 1/programmed cell death protein ligand 1 (PD-1/PD-L1) are key regulators in T-cell activation and tolerance. Nivolumab (PD-1 inhibitor) and Atezolizumab (PD-L1 inhibitor) are monoclonal antibodies approved for the treatment of several types of advanced cancers. Immune checkpoint inhibition caused by these drugs can result in immune-related adverse events (irAEs) New-onset diabetes mellitus has been reported in fewer than 1% of patients an...